neuer boom?! Champignon Brands! WKN: A3CPBM ISIN: CA1057361026 Kürzel: BRAXF Forum: Aktien User: Tycoon4965

0,00245 USD
±0,00 %±0,00000
21. Dec, 02:10:00 Uhr, Nasdaq OTC
Kommentare 1.237
Heisenberg25
Heisenberg25, 04.03.2023 11:34 Uhr
0
Was denkt Ihr ?
Heisenberg25
Heisenberg25, 04.03.2023 11:23 Uhr
0
Also ich denke das das ding diesen Monat noch richtig fliegt, wegen dem Buyout geduld meine meinung
Heisenberg25
Heisenberg25, 20.02.2023 19:52 Uhr
0
😏
Heisenberg25
Heisenberg25, 20.02.2023 19:52 Uhr
0
Soll mal wie troika steigen oder wie Tonix damals
N
Nobroken123, 20.02.2023 15:14 Uhr
0

Kommt da eigentlich nich was oder tut sich da nichts mehr ?

Wenn wir das alle wüssten 😅
Heisenberg25
Heisenberg25, 17.02.2023 20:55 Uhr
0
Noch*
Heisenberg25
Heisenberg25, 17.02.2023 20:54 Uhr
0
Kommt da eigentlich nich was oder tut sich da nichts mehr ?
N
Nobroken123, 28.01.2023 15:05 Uhr
0
Puh das kann ich dir nicht sagen.. aber wenn wir selber auch nochmal günstig alle nachkaufen und unseren eigenen Einkauf senken kann ich mich gut vorstellen das es gut steigen wird! Nur meine Meinung
M
Mirko_7, 28.01.2023 12:59 Uhr
0
Was seht ihr so als realistisches Ziel?
N
Nobroken123, 28.01.2023 12:39 Uhr
0
Wissen wohl nur Insider. Kann mir aber gut vorstellen das es noch steigen wird
M
Mirko_7, 28.01.2023 10:53 Uhr
0
glaubt ihr wird es steigen?
S
Smily, 27.01.2023 20:43 Uhr
0
Etwas abwarten - das mache ich jetzt.
N
Nobroken123, 27.01.2023 20:09 Uhr
0

LOS ANGELES, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is pleased to announce it has entered into a non-binding amended and restated Letter of Intent (“LOI”) for a business combination with Braxia Scientific Corp. (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares (the “Braxia Shares”) of Braxia (the “Proposed Transaction”). Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30,000,000 and a deemed value per subordinate voting share (“Irwin Share”) and/or proportionate voting share of Irwin (“Consideration Shares”) equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the Canadian Securities Exchange (the ”CSE”) for the 20 trading days immediately prior to the execution of the Arrangement Agreement. The purchase price would be payable on closing of the Proposed Transaction (the “Closing Date”) by the issuance of Consideration Shares to each holder of Braxia Shares. Based on the closing price of Irwin Shares and Braxia Shares on the CSE on January 25, 2023 of C$3.80 and C$0.05, respectively, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia Shares. The number of Consideration Shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than US$30,000,000, to be determined at a specified period of time after the Closing Date and as set forth in the Arrangement Agreement. The final purchase price per Braxia Share and the exchange ratio will be set forth and determined at the time the Arrangement Agreement is executed. The LOI further provides that the Consideration Shares would be subject to a lock-up period (the “Lock-Up”) and would be restricted from transfer or sale for a period of 6 months after the Closing Date. Insiders of Braxia would be subject to a Lock-Up period of 12 months from the Closing Date. Additionally, under the terms of the LOI and in connection with the Proposed Transaction, it is expected that the convertible securities of Braxia would, pursuant to the Arrangement Agreement, either remain outstanding in accordance with their terms or be exchanged for substantially similar securities of Irwin. The LOI is non-binding and there is no assurance that the Proposed Transaction will be completed as proposed. The completion of the Proposed Transaction is subject to, among other things (i) completion of satisfactory due diligence by each of Braxia and Irwin; (ii) negotiation of and the entering into of a binding definitive Arrangement Agreement in connection with the Proposed Transaction; (iii) receipt of all required corporate approvals from the board of directors of Braxia and Irwin, respectively, and all regulatory and shareholder approvals, including the approval of the CSE and any required third-party consents; and (iv) Braxia having at least C$575,000 in working capital immediately before closing on the Closing Date. Creating a New Market Leader in US and North American Mental Health The combined business creates a new market leader with operations in multiple markets in the US (~40+ markets) and in Canada across three important business verticals:

Was ist jetzt euer Plan? Nochmal welche nachkaufen? Oder abwarten?
S
Smily, 27.01.2023 17:02 Uhr
0
LOS ANGELES, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is pleased to announce it has entered into a non-binding amended and restated Letter of Intent (“LOI”) for a business combination with Braxia Scientific Corp. (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares (the “Braxia Shares”) of Braxia (the “Proposed Transaction”). Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30,000,000 and a deemed value per subordinate voting share (“Irwin Share”) and/or proportionate voting share of Irwin (“Consideration Shares”) equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the Canadian Securities Exchange (the ”CSE”) for the 20 trading days immediately prior to the execution of the Arrangement Agreement. The purchase price would be payable on closing of the Proposed Transaction (the “Closing Date”) by the issuance of Consideration Shares to each holder of Braxia Shares. Based on the closing price of Irwin Shares and Braxia Shares on the CSE on January 25, 2023 of C$3.80 and C$0.05, respectively, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia Shares. The number of Consideration Shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than US$30,000,000, to be determined at a specified period of time after the Closing Date and as set forth in the Arrangement Agreement. The final purchase price per Braxia Share and the exchange ratio will be set forth and determined at the time the Arrangement Agreement is executed. The LOI further provides that the Consideration Shares would be subject to a lock-up period (the “Lock-Up”) and would be restricted from transfer or sale for a period of 6 months after the Closing Date. Insiders of Braxia would be subject to a Lock-Up period of 12 months from the Closing Date. Additionally, under the terms of the LOI and in connection with the Proposed Transaction, it is expected that the convertible securities of Braxia would, pursuant to the Arrangement Agreement, either remain outstanding in accordance with their terms or be exchanged for substantially similar securities of Irwin. The LOI is non-binding and there is no assurance that the Proposed Transaction will be completed as proposed. The completion of the Proposed Transaction is subject to, among other things (i) completion of satisfactory due diligence by each of Braxia and Irwin; (ii) negotiation of and the entering into of a binding definitive Arrangement Agreement in connection with the Proposed Transaction; (iii) receipt of all required corporate approvals from the board of directors of Braxia and Irwin, respectively, and all regulatory and shareholder approvals, including the approval of the CSE and any required third-party consents; and (iv) Braxia having at least C$575,000 in working capital immediately before closing on the Closing Date. Creating a New Market Leader in US and North American Mental Health The combined business creates a new market leader with operations in multiple markets in the US (~40+ markets) and in Canada across three important business verticals:
N
Nobroken123, 27.01.2023 16:51 Uhr
0

LOI für Fusion

Du weißt was passiert ist? Magst du uns aufklären?
Mehr zu diesem Wert
Thema
1 neuer boom?! Champignon Brands!
2 Braxia
Meistdiskutiert
Thema
1 Brainchip Klassengruppe ±0,00 %
2 XIAOMI CORP. CL.B Hauptdiskussion +0,10 %
3 GEVO Hauptdiskussion ±0,00 %
4 BRAINCHIP HOLDINGS LTD Hauptdiskussion ±0,00 %
5 MICROSTRATEGY Hauptdiskussion ±0,00 %
6 IonQ +17,71 %
7 Dax Prognose -0,40 %
8 TESLA MOTORS Hauptdiskussion +0,04 %
9 CD PROJEKT Hauptdiskussion +0,07 %
10 BED BATH & BEYOND Hauptdiskussion ±0,00 %
Alle Diskussionen
Aktien
Thema
1 Brainchip Klassengruppe ±0,00 %
2 XIAOMI CORP. CL.B Hauptdiskussion +0,10 %
3 GEVO Hauptdiskussion ±0,00 %
4 BRAINCHIP HOLDINGS LTD Hauptdiskussion ±0,00 %
5 MICROSTRATEGY Hauptdiskussion ±0,00 %
6 IonQ +17,62 %
7 TESLA MOTORS Hauptdiskussion +0,04 %
8 CD PROJEKT Hauptdiskussion +0,07 %
9 BED BATH & BEYOND Hauptdiskussion ±0,00 %
10 Aktuelles zu Almonty Industries ±0,00 %
Alle Diskussionen